Navigation Links
Report documents cardiopulmonary arrest in premature infant after cyclomydril eyedrops
Date:4/3/2014

San Francisco, CA, April 2, 2014 Eyedrops administered to infants as part of routine outpatient retinopathy of prematurity (ROP) screening can have life-threatening consequences. A case report published in the current issue of the Journal of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS) describes cardiopulmonary arrest in a 27-week-old infant following administration of three sets of cyclopentolate 0.2%/phenylephrine 1% (Cyclomydril) eyedrops.

"Cardiopulmonary arrest can occur from just instillation of eyedrops in a premature infant seen for ROP in an outpatient setting, and pediatric ophthalmologists should be prepared to handle such an emergency in their office," says Sylvia Kodsi, MD, Professor of Ophthalmology at Hofstra North Shore-LIJ School of Medicine. "This can be particularly perilous in outpatient offices where patient monitoring and emergency back-up is not as readily available as in the hospital setting."

Retinopathy of prematurity is one of the most common causes of impaired vision in children and can lead to severe visual impairment and blindness. ROP primarily affects premature infants who weigh 2.75 pounds or less who are born before 31 weeks of gestation. Each year, about 28,000 infants in the U.S. fall into this category and about half are affected to some degree by ROP. About 400-600 of these children with ROP become legally blind. ROP occurs when babies are born before blood vessels in the eye have had a chance to reach the edges of the retina. Abnormal blood vessels form, resulting in inadequate blood supply, retinal scarring, and retinal detachment.

Professional organizations such as the American Association for Pediatric Ophthalmology and Strabismus, American Academy of Pediatrics, and American Academy of Ophthalmology recommend that at-risk infants be regularly screened for changes associated with ROP. To conduct the examination, eyedrops are administered to dilate the pupil (mydriasis) and reduce eye movements by temporarily paralyzing eye muscles (cycloplegia).

In the case that was reported, a 27-week-old low-birth-weight infant presented for a follow-up ROP screening examination at 41 weeks' corrected gestational age. The patient had previously undergone several such examinations, beginning at 30 weeks' corrected gestational age and every 2 weeks thereafter. For all those examinations, the infant received three sets (one drop per eye) of Cyclomydril, a combination of cyclopentolate (an anticholinergic that blocks pupillary constriction and eye muscle contraction) and phenylephrine (an alpha-adrenergic agent that causes mydriasis).

Fifteen minutes after the last set of drops was administered, but prior to the eye examination, the baby suffered a cardiopulmonary arrest and was revived within a few minutes. After transport to the hospital, she experienced another episode of apnea (breathing difficulty) and bradycardia (slow heart rhythm) and was found to have new-onset pulmonary hypertension.

These serious events are most likely attributed to an adverse drug reaction to cyclopentolate. According to co-author Jung M. Lee, MD, an ophthalmology resident also affiliated with Hofstra North Shore-LIJ School of Medicine, the phenylephrine would have mostly been cleared by the time the patient experienced the second event of apnea and bradycardia three hours after instillation of the eyedrops. She cautions that other anticholinergic drugs such as tropicamide may have a similar side effect profile. For this child, subsequent dilated ROP examinations performed with tropicamide 1% and phenylephrine 2.5% were performed without incident.

"Eyedrops used for mydriasis and cycloplegia can be systemically absorbed and cause serious side effects, including oxygen desaturation, apnea, bradycardia, transient hypertension, delayed gastric emptying, and transient paralytic ileus. These effects can be more serious in infants because of their lower body mass and immature cardiovascular and nervous systems," cautions Dr. Kodsi. "Pediatric ophthalmologists should be equipped to handle this type of emergency, either personally or with ancillary services that are immediately available."


'/>"/>

Contact: Eileen Leahy
e.leahy@elsevier.com
732-238-3628
Elsevier Health Sciences
Source:Eurekalert

Related biology news :

1. Behind the scenes of the IPCC report, with Stanford scientists
2. Bacterial reporters that get the scoop
3. New markers for acute kidney injury reported
4. Report describes Central Hardwoods forest vulnerabilities, climate change impacts
5. FASEB releases its FY 2015 funding report
6. Report details multiple commercial uses of wireless sensor networks
7. Policies to green the economy must underpin UK recovery: New report
8. Arctic biodiversity under serious threat from climate change according to new report
9. Plastic shopping bags make a fine diesel fuel, researchers report
10. Panel issues report on gray wolf science
11. Smithsonian reports GMO soybean pollen threatens Mexican honey sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/19/2019)... ... July 18, 2019 , ... VetStem Biopharma has ... experience. As a result of a two-year research collaboration with Calidi Biotherapeutics, ... virus platform in veterinary medicine. VetStem should be able to fast-track this cancer ...
(Date:7/17/2019)... ... July 18, 2019 , ... Flagship Biosciences, the ... PMP, to its executive team as Vice President of Operations. Ms. James brings ... her new role, Ms. James is responsible for ensuring on-time delivery of all ...
(Date:7/17/2019)... ... July 15, 2019 , ... ... for Life Sciences and Healthcare companies, announces the availability of new specialty advisory ... strategic direction to start-up and emerging bio-pharma companies interested in achieving specific outcomes ...
Breaking Biology News(10 mins):
(Date:5/31/2019)... ... May 29, 2019 , ... ... USPTO providing proprietary interest to our methodology, processes, and diagnostic techniques. The ... TREATMENT… extends Somnology’s IP rights including our proprietary sleep scoring methodology. The ...
(Date:5/31/2019)... ... May 30, 2019 , ... ... demonstrate an efficient delivery system for the sustained release of human placental stem ... gel system was able to deliver CM into the injured kidney, where it ...
(Date:5/15/2019)... , ... May 15, 2019 , ... Milton Hershey School® ... recognition for his work within the biomedical industry, where he is changing lives by ... devices. , “William Harding epitomizes the vision of our founders – Milton and ...
(Date:5/14/2019)... ... May 14, 2019 , ... Gateway Genomics , ... doubling its space from 2,500 to 5,000 square feet. , “This past year ... tests ,” says Gateway Genomics CEO, Chris Jacob. “The SneakPeek At-Home test, which is ...
Breaking Biology Technology: